Peptides for women: the approved options and what is still untested

For women, the useful question is which approved peptide drugs carry rules written specifically for women, because those rules come from trials. The list is short: bremelanotide for low sexual desire, the GLP-1 drugs with their pregnancy, contraception and breastfeeding instructions, abaloparatide for postmenopausal osteoporosis, and oxytocin for labor. Almost everything else sold as a peptide has never been tested in women at all. Other goals are in the peptides by goal index.

Approved peptides with female-specific label points

What are women usually looking for?

Most searches for peptides for women come down to a handful of goals. For each, the honest starting point is whatever has an FDA label.

Skin is the other common goal, and the evidence there is mostly about creams; the peptides for skin page covers it.

Bremelanotide (Vyleesi) in detail

Bremelanotide is the drug behind the research code PT-141. The PT-141 guide covers it in full; the label facts that matter most are these.

What the trials showed. Two identical 24-week trials randomized 1,267 premenopausal women with HSDD lasting at least six months to bremelanotide (635) or placebo (632), used as needed before sexual activity. On a desire score running from 1.2 to 6, the average rose by 0.5 and 0.6 on bremelanotide against 0.2 on placebo, and distress about low desire fell more than on placebo. There was no significant difference in the number of satisfying sexual events, a secondary endpoint.

How the label says it is used. It is a 1.75 mg autoinjector under the skin of the abdomen or thigh, at least 45 minutes before expected sexual activity. The label says not to use more than one dose in 24 hours, because doses close together may add to the blood pressure rise, and does not recommend more than 8 doses a month. Few trial patients used more than that, and more frequent use raises the risk of skin darkening.

Side effects on the label. Nausea in 40% of patients, with 13% needing anti-nausea medicine and 8% stopping early. Blood pressure rises and heart rate falls briefly after each dose, usually settling within 12 hours. Focal darkening of the skin, gums or breasts in 1%, more often with darker skin and daily use, and not always reversible. The label also says to avoid it with oral naltrexone products used for alcohol or opioid addiction, because it can sharply lower naltrexone levels.

Who it is not for. Postmenopausal women, men, anyone wanting better sexual performance, and anyone whose low desire is due to another medical or psychiatric condition, relationship problems, or a medication.

GLP-1 drugs: contraception, pregnancy and breastfeeding

The two most prescribed peptide drugs differ in ways that matter for women.

• Tirzepatide and the pill. The Zepbound label explains that slower stomach emptying can reduce absorption of oral hormonal contraceptives, with the biggest effect after the first dose. Its advice is to switch to a non-oral method or add a barrier method for 4 weeks after starting and after every dose step. Non-oral hormonal methods should not be affected.
• Semaglutide and the pill. The Wegovy label reports no clinically significant change in ethinyl estradiol or levonorgestrel when taken with semaglutide, and does not carry the same backup advice. Its pregnancy instruction is the stricter one: stop at least 2 months before a planned pregnancy.
• Pregnancy. Weight loss offers no benefit in pregnancy, and the Zepbound label says to stop when pregnancy is recognized. The label lists a pregnancy exposure registry, run through Lilly, for women exposed to Zepbound.
• Breastfeeding on tirzepatide. In a lactation study of 11 women given a single 5 mg dose, tirzepatide was undetectable in 164 of 171 milk samples, and the total found was less than 0.02% of the dose. There are no data on the breastfed baby or on milk supply.
• Breastfeeding on semaglutide. The forms differ. The tablets contain an absorption enhancer, SNAC, that passes into milk and may build up in infants, so the label says breastfeeding is not recommended on Wegovy tablets. For the injection, which has no SNAC, there are no data on milk at all.
• Hair. A 2026 systematic review of GLP-1 drugs and hair loss found women appeared to be disproportionately affected; the hair growth page covers that.

For Zepbound and the Wegovy injection, the labels ask the mother and prescriber to weigh the benefits of breastfeeding against her need for the drug.

Abaloparatide (Tymlos) for bone

Abaloparatide is a daily injection that builds bone, and its main trial was in women. In that trial, postmenopausal women with osteoporosis had new vertebral fractures at 0.6% over 18 months on abaloparatide against 4.2% on placebo, an 86% relative reduction. Participants also took calcium and vitamin D.

The label carries several points worth knowing before the first dose:

• Time limit. Safety and effectiveness have not been evaluated beyond 2 years, and use for more than 2 years in a lifetime is not recommended.
• Dizziness on standing. Blood pressure can drop when standing up, so the label says to give the first several doses where the patient can sit or lie down.
• Bone cancer in rats. Abaloparatide caused osteosarcoma in rats at exposures 4 to 28 times the human dose. Whether it does so in people is unknown; osteosarcoma has been reported after approval with drugs of this type, though observational studies have not shown a higher risk. The label says to avoid it in people at higher risk, such as those with Paget’s disease, bone cancer or past radiation therapy involving the skeleton.
• Calcium. It should be avoided with existing high blood calcium, and urine calcium monitored if kidney stones are suspected.

Hot flashes and menopause

No peptide is approved to treat hot flashes. The approved nonhormonal pill fezolinetant (Veozah) is relevant here because of how it works: the label says it “blocks neurokinin B (NKB) binding” on the KNDy neurons, named for kisspeptin, neurokinin B and dynorphin, in the brain’s temperature-control center. Neurokinin B is a peptide, so the approved medicine here blocks a peptide signal instead of supplying one.

Veozah is a 45 mg tablet once a day for moderate to severe hot flashes due to menopause. It carries a boxed warning for liver injury seen after approval. The label calls for liver blood tests before starting, monthly for the first 3 months, then at 6 and 9 months, and says to stop and get tested for new fatigue, nausea, itching, yellow skin or eyes, pale stools or dark urine. In three trials, liver enzyme rises above 3 times normal occurred in 2.3% of women on Veozah and 0.9% on placebo. It is contraindicated with known cirrhosis, severe kidney disease, and drugs that block the liver enzyme CYP1A2.

What is unstudied in women

• Most peptides sold online. BPC-157, TB-500, CJC-1295, ipamorelin and the rest have no controlled human trials in anyone. A 2025 systematic review of BPC-157 found 35 animal studies and one uncontrolled chart review. There is no information on effects in women, in pregnancy, with contraception, or in breastfeeding.
• Growth hormone releasing drugs. Tesamorelin’s main NEJM trial was 86% men, and the drug is contraindicated in pregnancy. In a 1997 study of a GHRH 1-29 analog in older adults, lean mass, insulin sensitivity, well-being and libido improved in men but not in women.
• Bremelanotide after menopause. The two phase 3 trials enrolled premenopausal women only, and the label excludes postmenopausal women.

An HHS policy from October 2026 does not change that list. As of November 2, 2026, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding six peptides, including BPC-157 and TB-500, if ten conditions are met. None of the six is FDA-approved, the policy is not binding and creates no rights, it covers 503A compounding only, states can be stricter, and it says nothing about safety in women or in pregnancy. Blends fall outside it, because each product must contain a single active ingredient. Comments are open until November 13, 2026.

Legal position

The drugs in the tables are legal with a prescription. Products sold online as PT-141, or as any unapproved peptide, with a “research use only” label may legally be shipped only for laboratory or animal tests under 21 CFR 312.160. They are not legal to use on people. The FDA status tracker lists the status of each peptide.

Questions to ask a prescriber

• If I am on the pill, does this drug change how well it works, and for how long?
• How long before trying to conceive should I stop, and what happens if I get pregnant while taking it?
• Is it compatible with breastfeeding, and does the form (tablet or injection) matter?
• For bone drugs, how long can I stay on it, and what comes after?
• What symptoms mean I should stop and call?